Full Press Release Details
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric ™ and EFECT ™ Therapeutic Platforms.
ZYME
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric ™ and EFECT ™ Therapeutic Platforms
Key Takeaway: Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric ™ and EFECT ™ Therapeutic Platforms
Price reaction · baseline $20.11 (2021-11-30 close) · hit after-hours · clean, no other ZYME news in the window
day 0 close · peak
+0.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers